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Purpose: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), Everolimus-eluting stent (EES) and 
SeQuent™ Please, a drug-eluting balloon (DEB) on the outcome of patients with diffuse in-stent restenosis (D-ISR) after bare metal stent (BMS) 
implantation.
Methods: A prospective analysis of 911 patients with 1080 D-ISR lesions (384 SES, 334 PES, 221 EES and 141 DEB) in six high volume Asian 
centers after successful stent implantation (SES: LAD 45.7%, LCX 27.8%, RCA 26.5%) (PES: LAD 46.1%, LCX 22.9%, RCA 31.0%) (EES: LAD 50.0%, 
LCX 21.3%, RCA 28.7%) (DEB: LAD 54.1%, LCX 22.8%, RCA 23.1%) was performed. The study endpoints were major adverse cardiac events (MACE) at 
12 months, restenosis rate and target lesion revascularization (TLR) at 12 months.
Results: See table for clinical results.
Conclusion: (1) The use of SES, PES, EES and DEB in patients with D-ISR seems to be favorable in terms of in-hospital clinical outcome. (2) 
Patients treated with DEB showed higher restenosis rate and TLR compared with DES. 
SES PES EES DEB
Number of patients/lesions 320/384 294/334 188/221 109/141
Procedural success (%) 100 100 100 98.1
MACE at 30 days (%) 0.9 1.0 0 1.5
Proximal RD (mm) 2.86±0.74 2.80±0.80 2.79±0.71 2.81±0.79
MLD post procedure (mm) 2.60±0.77 2.61±0.74 2.66±0.71 2.28±0.78
MLD 6 months (mm) 2.41±0.80 2.29±0.72 2.50±0.60 2.01±0.79
MLD 12 months (mm) 2.33±0.79 2.19±0.75 2.44±0.71 1.89±0.89
Restenosis rate (%) 7.5 11.5 5.3 28.4*
TLR (%) 6.9 11.5 5.3 27.5*
MACE at 12 months (%) 7.8 12.5 5.3 29.0*
RD: reference diameter, MLD: minimum lumen diameter, *p<0.05 vs SES, PES and EES.
